Cite
HARVARD Citation
Zhu, A. et al. (n.d.). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet oncology. 16 (7), pp. 859-870. [Online].